Accelr8 Technology Corporation (NYSE Amex: AXK) announced results presented at the 51 st ICAAC held in Chicago on September 17. As previously announced in July, the presenters received an award for an “outstanding presentation of an abstract accepted by ICAAC.” The presentation title is “Same-Shift ID Directly from Respiratory Specimens by Automated Microscopy.” It reported results from a study using Accelr8’s BACcel™ rapid diagnostic system in collaboration with investigators at the Barnes-Jewish Hospital in St. Louis. The study reported results with 53 bacteria-positive lung specimens from ICU patients. Of these, 16 were positive for the two most common ICU pathogens that can express multi-drug resistance (MDR)— Staphylococcus aureus (the common “Staph”) and Pseudomonas aeruginosa. The latter Gram-negative organism is one of the most complex and difficult to treat MDR threats found in hospital-acquired infections. Accelr8’s BACcel™ rapid diagnostic system correctly identified 9/9 S. aureus and 7/7 P. aeruginosa directly from specimen samples. It also correctly identified the lack of these target organisms in the remaining 37 specimens, yielding detection sensitivity and specificity of 100% and 100%, respectively. The Accelr8 Web site has a downloadable copy of the presentation at www.accelr8.com/pgen.php?pg=resources_publications. ICAAC ( www.icaac.org) is the annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Organized by the American Society for Microbiology ( www.asm.org), ICAAC is a major global congress for Clinical Microbiology and Infectious Diseases Medicine. According to David Howson, Accelr8’s president, “We are honored by the recognition from ICAAC’s review committee. Results in our outside studies continue to strongly support the system’s accuracy and speed. The BACcel™ system continues as the only new technology to demonstrate multiple organism quantitative identification with multiple antibiotic resistance detection. The BACcel system stands alone in directly confronting the relentlessly advancing global pandemic of multiple antibiotic resistance.”
About Accelr8Accelr8 Technology Corporation ( www.accelr8.com) is a developer of innovative materials and instrumentation for advanced applications in medical instrumentation, basic research, drug discovery, and bio-detection. Accelr8 is developing a rapid analytical platform for infectious pathogens, the BACcel™ system, based on its innovative surface coatings, assay processing, and detection technologies. In addition, Accelr8 licenses certain of its proprietary technology for use in applications outside of Accelr8’s own products. Certain statements in this news release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding future prospects and developments are based upon current expectations and involve certain risks and uncertainties that could cause actual results and developments to differ materially from the forward-looking statement, including those detailed in the company's filings with the Securities and Exchange Commission. Accelr8 does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events.